tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Esposito C et al. Sirolimus prevents short-term renal changes induced by ischemia-reperfusion injury in rats. 2011 Am. J. Nephrol. pmid:21358177
Ren H et al. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. 2013 Am. J. Nephrol. pmid:23343906
Ferreira A et al. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus. 2017 Am. J. Nephrol. pmid:28511172
Tsipotis E et al. Bioavailability, Efficacy and Safety of Generic Immunosuppressive Drugs for Kidney Transplantation: A Systematic Review and Meta-Analysis. 2016 Am. J. Nephrol. pmid:27576318
Issa N et al. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. 2013 Am. J. Nephrol. pmid:23796509
Taber DJ et al. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients. 2014 Am. J. Nephrol. pmid:24969370
Li J et al. Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients. 2013 Am. J. Nephrol. pmid:23689735
Lee CT et al. Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. 2011 Am. J. Nephrol. pmid:21691056
Soubhia RM et al. Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided. 2005 Jul-Aug Am. J. Nephrol. pmid:15976495
El-Dahshan KF et al. Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. 2006 Am. J. Nephrol. pmid:16804292
Weir MR et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. 2004 Jul-Aug Am. J. Nephrol. pmid:15237243
Bagnis C et al. Comparative acute nephrotoxicity of FK-506 and ciclosporin in an isolated in situ autoperfused rat kidney model. 1997 Am. J. Nephrol. pmid:9057948
Chen W et al. Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: a prospective, multicenter clinical trial. 2013 Am. J. Med. Sci. pmid:22627258
Hsu MS et al. Clinical features and outcome of tuberculosis in solid organ transplant recipients. 2007 Am. J. Med. Sci. pmid:17700199
Ocampo-Garza J et al. Acquired Hyperpigmentation and Cicatricial Alopecia. 2016 Am. J. Med. Sci. pmid:27524226
Chen M et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. 2010 Am. J. Med. Sci. pmid:20220333
Bar J et al. Is immunosuppression therapy in renal allograft recipients teratogenic? A single-center experience. 2003 Am. J. Med. Genet. A pmid:12476448
Perez-Aytes A et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? 2008 Am. J. Med. Genet. A pmid:18074358
Lien YH Top 10 Things Primary Care Physicians Should Know About Maintenance Immunosuppression for Transplant Recipients. 2016 Am. J. Med. pmid:26714210
Tang S and Lai KN Quiz page. Posttransplantation lymphoproliferative disorder (PTLD) involving the brain and the allograft. 2005 Am. J. Kidney Dis. pmid:15806458
Rao PS Nephrotic syndrome in patients with peripheral blood stem cell transplant. 2005 Am. J. Kidney Dis. pmid:15806483
de Mattos AM et al. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. 2000 Am. J. Kidney Dis. pmid:10676738
Kooman JP et al. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. 2001 Am. J. Kidney Dis. pmid:11382685
Choudhry S et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. 2009 Am. J. Kidney Dis. pmid:19268410
Birdwell KA et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. 2009 Am. J. Kidney Dis. pmid:19185404
Haas M et al. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. 1999 Am. J. Kidney Dis. pmid:10401019
Wong TY et al. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. 1999 Am. J. Kidney Dis. pmid:10585325
Rostaing L et al. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. 2016 Am. J. Kidney Dis. pmid:26717860
Hricik DE Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients. 2001 Am. J. Kidney Dis. pmid:11583939
Pescovitz MD and Govani M Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. 2001 Am. J. Kidney Dis. pmid:11583940
Tang S et al. Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome. 2003 Am. J. Kidney Dis. pmid:14582073
Pham PT et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. 2000 Am. J. Kidney Dis. pmid:11007689
Revelo MP et al. A 14-year-old boy with kidney allograft failure in the first month after transplantation. 2000 Am. J. Kidney Dis. pmid:11007695
Lien YH and Bracamonte ER Quiz page February 2011: acute kidney injury, graft pain, and subtherapeutic levels of tacrolimus. 2011 Am. J. Kidney Dis. pmid:21251536
Pavan M et al. Altered bioavailability of tacrolimus following intravenous administration of tigecycline. 2011 Am. J. Kidney Dis. pmid:21251548
Vischini G et al. Increased plasma levels of tacrolimus after ingestion of green tea. 2011 Am. J. Kidney Dis. pmid:21787983
van Duijnhoven EM et al. A late episode of post-transplant diabetes mellitus during active hepatitis C infection in a renal allograft recipient using tacrolimus. 2002 Am. J. Kidney Dis. pmid:12087579
Moes AD et al. Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. 2017 Am. J. Kidney Dis. pmid:28259499
Wong KM et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. 2000 Am. J. Kidney Dis. pmid:10739787
Böhmig GA et al. Role of humoral immune reactions as target for antirejection therapy in recipients of a spousal-donor kidney graft. 2000 Am. J. Kidney Dis. pmid:10739788
Starzl TE et al. Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. 1998 Am. J. Kidney Dis. pmid:9631858
Li X et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. 2009 Am. J. Kidney Dis. pmid:19406543
Al-Awwa IA et al. Importance of allograft biopsy in renal transplant recipients: correlation between clinical and histological diagnosis. 1998 Am. J. Kidney Dis. pmid:9631859
Lum EL et al. Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma. 2017 Am. J. Kidney Dis. pmid:28189378
Neylan JF et al. Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. 1998 Am. J. Kidney Dis. pmid:9820446
Chen W et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. 2011 Am. J. Kidney Dis. pmid:21177013
First MR Renal transplantation for the nephrologist: new immunosuppressive drugs. 1992 Am. J. Kidney Dis. pmid:1371201
Paoletti E et al. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. 2007 Am. J. Kidney Dis. pmid:17591533
Mertz D et al. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. 2009 Am. J. Kidney Dis. pmid:19346040
Israni A et al. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. 2002 Am. J. Kidney Dis. pmid:11877596
Soi V et al. Altered mental status in a kidney transplant recipient receiving tacrolimus. 2008 Am. J. Kidney Dis. pmid:18155524
Reese PP et al. Automated Reminders and Physician Notification to Promote Immunosuppression Adherence Among Kidney Transplant Recipients: A Randomized Trial. 2017 Am. J. Kidney Dis. pmid:27940063
Mathis AS and Friedman GS Coadministration of digoxin with itraconazole in renal transplant recipients. 2001 Am. J. Kidney Dis. pmid:11157404
Tsinalis D et al. Acute renal failure in a renal allograft recipient treated with intravenous immunoglobulin. 2002 Am. J. Kidney Dis. pmid:12200824
Asif A et al. Peritoneoscopic placement of peritoneal dialysis catheter and bowel perforation: experience of an interventional nephrology program. 2003 Am. J. Kidney Dis. pmid:14655200
Grinyó JM et al. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. 2017 Am. J. Kidney Dis. pmid:27889299
Cohen DL et al. Pulse wave analysis to assess vascular compliance changes in stable renal transplant recipients. 2004 Am. J. Hypertens. pmid:15001192
Zhang W and Victor RG Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. 2000 Am. J. Hypertens. pmid:10981550
Taler SJ et al. Loss of nocturnal blood pressure fall after liver transplantation during immunosuppressive therapy. 1995 Am. J. Hypertens. pmid:7544983
Nara M et al. Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3. 2010 Am. J. Hematol. pmid:20568249
Lekakis LJ et al. BK virus nephropathy after allogeneic stem cell transplantation: a case report and literature review. 2009 Am. J. Hematol. pmid:19208419
Hammerstrom AE et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. 2013 Am. J. Hematol. pmid:23460378
Abdel-Azim H et al. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. 2015 Am. J. Hematol. pmid:26242764
Uehara T et al. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection. 2004 Am. J. Hematol. pmid:15282671
Nakamae H et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. 2006 Am. J. Hematol. pmid:16755559
Bolaños-Meade J et al. Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung. 2005 Am. J. Hematol. pmid:15929116
Ninan MJ and Datta YH Post-transplant lymphoproliferative disorder presenting as multiple myeloma. 2010 Am. J. Hematol. pmid:20578201
Mach-Pascual S et al. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. 1996 Am. J. Hematol. pmid:8701950
Uehara T et al. A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT. 2002 Am. J. Hematol. pmid:12221672
Rudi J et al. Prevalence of serum antibodies to Helicobacter pylori and to CagA protein in liver transplant recipients. 1997 Am. J. Gastroenterol. pmid:9317070
Van Thiel DH et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7532912
Baumgart DC et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. 2006 Am. J. Gastroenterol. pmid:16573777
Sandborn WJ Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. 1997 Am. J. Gastroenterol. pmid:9149205
Van Thiel DH et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7537444
Fellermann K et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). 1998 Am. J. Gastroenterol. pmid:9772045
Stickle DF et al. Effects of sterilizing gamma irradiation on bloodspot newborn screening tests and whole blood cyclosporine and tacrolimus measurements. 2003 Am. J. Clin. Pathol. pmid:12580001
Wang E et al. Pseudo-Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huët anomaly. 2011 Am. J. Clin. Pathol. pmid:21228370
Burke MT et al. Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients. 2015 Am. J. Clin. Pathol. pmid:25780003
Lower DR et al. Comparison of CEDIA FK506 assay with HPLC/MS/MS in a large cohort of pediatric patients. 2013 Am. J. Clin. Pathol. pmid:23690122
Hisamura F et al. Synergistic effect of green tea polyphenols on their protection against FK506-induced cytotoxicity in renal cells. 2008 Am. J. Chin. Med. pmid:18543393
Chung SY et al. Ginkgo biloba leaf extract (EGb761) combined with neuroprotective agents reduces the infarct volumes of gerbil ischemic brain. 2006 Am. J. Chin. Med. pmid:17080546
Chieffo A et al. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. 2009 Am. J. Cardiol. pmid:19962471
Chang RK et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. 1998 Am. J. Cardiol. pmid:9604971
Klauss V et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. 2000 Am. J. Cardiol. pmid:10955391
Herzberg GZ et al. Usefulness of tacrolimus versus cyclosporine after pediatric heart transplantation. 1998 Am. J. Cardiol. pmid:9723652
Kodama M et al. FK506 therapy of experimental autoimmune myocarditis after onset of the disease. 1993 Am. Heart J. pmid:7504393
Azizian M et al. Augmentation of ischemia/reperfusion injury to endothelial cells by cyclosporin A. 2004 Am Surg pmid:15156953
Henderson CN et al. Continuous Abdominal Irrigation for Treatment of Tertiary Peritonitis in the Immunosuppressed Patient after Solid Organ Transplant: A Novel Approach. 2017 Am Surg pmid:28424115
Rojas-García P et al. Breast fibroadenomas associated with immunosuppressive drugs. 2010 Am Surg pmid:21418766
Vearrier D et al. Mutism and persistent dysarthria due to tacrolimus-based immunosuppression following allogeneic liver transplantation. 2011 Am J Ther pmid:20535006
Yang A and Wang B Sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids: focus on acute rejection, patient and graft survival. Am J Ther pmid:23921809
Pariser D Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. 2009 May-Jun Am J Ther pmid:19262357
Sathyan S et al. Prevention of recurrent episodes of rhabdomyolysis with tacrolimus in a transplant recipient with myopathy. Am J Ther pmid:23429166
Liu JY et al. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther pmid:25299636
Haroon N et al. Tacrolimus Toxicity With Minimal Clinical Manifestations: A Case Report and Literature Review. Am J Ther pmid:25730156
Nunokawa T et al. Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report. Am J Ther pmid:22836123
Liu JY et al. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther pmid:25569597
Cohen SM Current immunosuppression in liver transplantation. 2002 Mar-Apr Am J Ther pmid:11897926
Yousuf Bhat Z et al. Colchicine-Induced Myopathy in a Tacrolimus-Treated Renal Transplant Recipient: Case Report and Literature Review. Am J Ther pmid:24732905
Moon BJ et al. Effect of chronic rhinosinusitis on liver transplant patients. 2009 Sep-Oct Am J Rhinol Allergy pmid:19807981